Results 11 to 20 of about 35,832 (220)

Preparation and physicochemical characterization of sildenafil cocrystals

Journal of Advanced Pharmaceutical Technology & Research, 2021
Sildenafil is a specific inhibitor of the phosphodiesterase type 5 (PDE-5) enzyme that protects cyclic guanosine monophosphate from breakdown by PDE-5. It is a biopharmaceutical categorization system Class II medication with low bioavailability because ...
Somchai Sawatdee, Apichart Atipairin, Supitchaya Rakkummerd, Onsinee Suriyaphol, David J Harding, Poowadon Muenraya, Phimphaka Harding   +6 more
doaj   +1 more source

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease

Nature Aging, 2021
We developed an endophenotype disease module-based methodology for Alzheimer’s disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier.
Jiansong Fang, Pengyue Zhang, Yadi Zhou, Chienwei Chiang, Juan Tan, Yuan Hou, S. Stauffer, Lang Li, A. Pieper, J. Cummings, F. Cheng   +10 more
semanticscholar   +1 more source

Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension

Scientific Reports, 2022
Sildenafil is widely used off-label in pediatric patients with pulmonary arterial hypertension (PAH). This study was conducted to characterize the pharmacokinetics (PK) of sildenafil in term and preterm neonates with PAH, by developing a population PK ...
Su-jin Rhee, Seung Han Shin, Jaeseong Oh, Young Hwa Jung, Chang Won Choi, Han-Suk Kim, Kyung-Sang Yu   +6 more
doaj   +1 more source

Oral Bioavailability and Pharmacokinetics of Sildenafil Orally Disintegrating Tablets under Various Gastric pH Levels Following Administration of Omeprazole in Rats

Life, 2023
Sildenafil citrate, an oral drug used to treat erectile dysfunction, has low water solubility and oral bioavailability. The solubility is greatly influenced by the pH, changing from 37.25 mg/mL to 0.22 mg/mL with a change in pH from 1.2 to 8.0.
Chin-Yu Shih, Chao-Yi Chen, Hsien-Te Lin, Ying-Ju Liao, Yao-Jen Liang   +4 more
doaj   +1 more source

Visual Side Effects Linked to Sildenafil Consumption: An Update

Biomedicines, 2021
Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra® (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased ...
Eva Ausó, V. Gómez-Vicente, Gema Esquiva   +2 more
semanticscholar   +1 more source

Identification, synthesis, and characterization of potential genotoxic impurities of sildenafil citrate drug substance

Future Journal of Pharmaceutical Sciences, 2020
Background Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specifil phophodiesterase type 5 (PDE5). Sildenafil enhances the effect of nitric oxide by inhibiting phosphodiesterase type 5, which is responsible for the ...
P. Rajesh Reddy, Sivanadh Musunuri, D. Rama Sekhara Reddy, V. Subrahmanyam Chittala, V. N. S. Murthy P, K. Krishnamohan   +5 more
doaj   +1 more source

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

Development of a Sildenafil Citrate Microemulsion-Loaded Hydrogel as a Potential System for Drug Delivery to the Penis and Its Cellular Metabolic Mechanism

Pharmaceutics, 2020
Sildenafil citrate is used to treat mild to moderate erectile dysfunction and premature ejaculation. However, it has low oral bioavailability, numerous adverse effects, and delayed onset of action.
Apichart Atipairin, Charisopon Chunhachaichana, Titpawan Nakpheng, Narumon Changsan, Teerapol Srichana, Somchai Sawatdee   +5 more
doaj   +1 more source

Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction

JAMA Network Open, 2020
Key Points Question Does sildenafil reduce the risk of perinatal mortality or morbidity in children of pregnant women with severe early onset fetal growth restriction?
A. Pels, J. Derks, A. Elvan‐Taşpınar, J. van Drongelen, M. D. de Boer, H. Duvekot, J. V. van Laar, J. van Eyck, S. Al-Nasiry, M. Sueters, M. Post, W. Onland, A. V. van Wassenaer-Leemhuis, C. Naaktgeboren, J. Jakobsen, C. Gluud, R. Duijnhoven, Titia Lely, S. Gordijn, W. Ganzevoort   +19 more
semanticscholar   +1 more source

HPLC-MS/MS Method for Quantitation of Sildenafil and Its Active Metabolite in Human Plasma

Регуляторные исследования и экспертиза лекарственных средств, 2020
A high demand for sildenafil-based drugs puts a premium on the development of methods for quantitation of sildenafil in bio-substrates to facilitate pharmacokinetic analysis in bioequivalence studies.
G. G. Rodionov, I. I. Shantyr, I. E. Ushal, E. V. Svetkina, E. A. Kolobova, K. A. Zakharov   +5 more
doaj   +1 more source